• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards | Inspections
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
 
Trade NameVITUOSO DR, VIRTUOSO VR, VIRTUOSO II DR, VIRTUOSO II VR, SECURA DR, SECURA VR, PROTECTA XT DR, PROTECTA XT VR
Classification Nameimplantable cardioverter defibrillator (non-crt)
Applicant MEDTRONIC INC.
PMA NumberP980016
Supplement NumberS389
Date Received11/07/2012
Decision Date02/05/2013
Product Code
LWS[ Registered Establishments with LWS ]
Advisory Committee Cardiovascular
Supplement Typenormal 180 day track
Supplement Reason labeling change - indications
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for clarifications to the indications for use statements related to the optivol feature and other modifications to the device labeling. The devices are indicated as follows: dual chamber icds the dr system is indicated to provide ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias. In addition, the device is indicated for use in the above patients with atrial tachyarrhythmias, or those patients who are at significant risk of developing atrial tachyarrhythmias. Notes: 1) the use of the device has not been demonstrated to decrease the morbidity related to atrial tachyarrhythmias. 2) the effectiveness of high-frequency burst pacing (atrial 50 hz burst therapy) in terminating device classified atrial tachycardia (at) was found to be 17%, and in terminating device classified atrial fibrillation (af) was found to be 16. 8%, in the vt/at patient population studied. 3) the effectiveness of high-frequency burst pacing (atrial 50 hz burst therapy) in terminating device classified atrial tachycardia (at) was found to be 11. 7%, and in terminating device classified atrial fibrillation (af) was found to 18. 2% in the af-only patient population studied. Single chamber icds: the vr system is indicated to provide ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias.
-
-